-
In order to achieve import substitution, pharmaceutical enterprises are constantly strengthening independent research and development
Time of Update: 2023-01-06
It is reported that after the landing of Dongfulongding's additional fundraising and investment project, it can extend the company's industrial chain, build an integrated industrial ecology of CGT (cell and gene therapy) pharmaceutical equipment, instruments and consumables, change the market pattern dominated by the import of some CGT pharmaceutical equipment, seize the opportunity of import substitution, and continuously increase market share in key areas.
-
The three departments have increased efforts to promote smart health and elderly care products and services
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];The reporter learned from the Ministry of Industry and Information Technology on the 23rd that the Ministry of Industry and Information Technology, the Ministry of Civil Affairs, and the National Health Commission recently issued a notice to organize the application of the 2022 smart health elderly care products and services promotion catalog.
-
Industry: Domestic innovative drugs are ushering in a good era of FIC and BIC
Time of Update: 2023-01-05
In addition to Hengrui and Fosun, many pharmaceutical companies entering the field of innovative drugs have continued to increase investment in R&D, and the number of new drugs approved in China has reached a record high.
-
Shanghai promotes the transformation of innovative traditional Chinese medicine: in-hospital preparations are expected to be officially launched
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];The reporter learned from the Shanghai Administration of Traditional Chinese Medicine on the 22nd that lung Yanning granules, Lu flexible granules, Longmu Qingxin granules.
js?cdnversion='+~(-new Date()/36e5)];The reporter learned from the Shanghai Administration of Traditional Chinese Medicine on the 22nd that lung Yanning granules, Lu flexible granules, Longmu Qingxin granules.
-
The traditional Chinese medicine sector performed strongly, with 2 more shares up and down
Time of Update: 2023-01-05
【Pharmaceutical Network Pharmaceutical Stock Market】On November 24, the traditional Chinese medicine sector performed strongly, and Fangsheng Pharmaceutical and Kangyuan Pharmaceutical both rose to the limit.
【Pharmaceutical Network Pharmaceutical Stock Market】On November 24, the traditional Chinese medicine sector performed strongly, and Fangsheng Pharmaceutical and Kangyuan Pharmaceutical both rose to the limit.
-
Another Chinese medicine stock won 7 days and 5 boards! Where does it come from?
Time of Update: 2023-01-05
Tailong Pharmaceutical recently replied to investors on the interactive platform, saying that the company's double jaundice oral liquid has been listed as a recommended drug for major diagnosis and treatment plans by the National Health Commission and the Administration of Traditional Chinese Medicine for many times.
-
Pharmaceutical ETF shares increased this month, boosting market confidence
Time of Update: 2023-01-05
In the case of an increase in the share of ETFs in the pharmaceutical industry, to a certain extent, it can be seen that funds are optimistic about the pharmaceutical sector, which will help boost market confidence.
-
Sprint to the Science and Technology Innovation Board! 2 pharmaceutical IPOs will be on the meeting
Time of Update: 2023-01-05
68 million shares will be issued this time According to the prospectus of Zhixiang Jintai's initial public offering and listing on the Science and Technology Innovation Board (Declaration Draft), the number of shares issued by the issuer this time is 91.
-
Ten days after the issuance of the "20 Articles", what measures have been adjusted for epidemic prevention and control in various places?
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];Since the issuance of the 20 measures to further optimize epidemic prevention and control (hereinafter referred to as the "20 measures") on the 11th, various localities have successively issued relevant adjustment policies for key areas of prevention and control such as nucleic acid testing and personnel control to further improve the scientificity, accuracy and effectiveness of epidemic prevention and control.
-
Japan urgently approved the first oral drug made in Japan
Time of Update: 2023-01-05
According to the relevant emergency approval system established in Japan in May this year, after the emergency approval of a drug, its manufacturer and seller must continue clinical trials to further confirm the effectiveness and safety of the drug, and apply for approval again within two years.
-
A new round of medical insurance negotiations is about to start, and differentiated innovative drug products have attracted much attention
Time of Update: 2023-01-05
According to the Essence Securities report, according to the List of Declared Drugs Passing the Preliminary Form Review, at least 22 domestic innovative drugs (including introduced products) participated in medical insurance negotiations for the first time in 2022.
-
How to carry out nucleic acid testing in various places? How to classify and manage high-risk and low-risk areas? ——The new document on the prevention and control mechanism of the State Council focuses on the highlights
Time of Update: 2023-01-05
After the introduction of the 20 optimization measures, the comprehensive group of the joint prevention and control mechanism of the State Council issued four documents on the 21st, namely the Implem
-
Many pharmaceutical stocks such as Cylon Pharmaceutical and ST Kangmei closed at the limit higher
Time of Update: 2023-01-05
Looking forward to the future market, CITIC Securities believes that in recent years, the state has vigorously supported the development of traditional Chinese medicine, and has continuously introduced relevant support policies, and the long-term development of traditional Chinese medicine has improved.
-
Traditional Chinese medicine stocks have changed frequently, and this pharmaceutical company has risen again
Time of Update: 2023-01-05
According to the data, Teyi Pharmaceutical is mainly engaged in the research and development, production and sales of proprietary Chinese medicines, chemical preparations and chemical APIs. Since November, the stock price of Teyi Pharmaceutical has risen particularly significantly, and the stock price has doubled within the month, reaching an increase of 101%, with a total market value of 6.
-
This market of monoclonal antibody varieties of more than 10 billion yuan has gradually become a red sea!
Time of Update: 2023-01-05
In addition, there are Taiboya of Chia Tai Tianqing and Henlius' Handayuan have been approved for more than 3 indications, plus the original research, a total of 7 domestic adalimumab.
-
The overall investment opportunities of pharmaceuticals in the future are still optimistic about the industry
Time of Update: 2023-01-05
The manager of Golden Eagle Medical and Health Industry Equity Fund also said that the investment opportunities in the pharmaceutical sector in the future are worth looking forward to.
-
Shisi Yao Class 1 new drugs ignited the 100 billion market, and 45 blockbuster new products rushed to market
Time of Update: 2023-01-05
In recent years, Shijiazhuang Four Medicines has vigorously promoted scientific research innovation and structural optimization business measures, persistently promoted the coordinated development of
-
The medical device sector is active, with many stocks rising more than 10%
Time of Update: 2023-01-05
The company is a company whose main business is the research and development, production, sales and service of medical device products, mainly covering two major business segments: health monitoring and renal medical care.
-
This Chinese medicine stock rose to the close, with a cumulative increase of more than 30% in the past 5 days
Time of Update: 2023-01-05
According to the Oriental Wealth Network Market Center's ranking of the flow of individual stock funds yesterday, Jinling Pharmaceutical ranked first with a net inflow of more than 50 million yuan, and the net inflow of the main force reached 52.
-
Shanghai Traditional Chinese Medicine Characteristic Services into the Community to Open Up the "Last Mile" of Quality Pharmaceutical Services
Time of Update: 2023-01-05
js?cdnversion='+~(-new Date()/36e5)];In order to meet the health needs of community residents for high-quality Chinese medicine, improve the service level of traditional Chinese medicine in community health sites, and let the traditional Chinese medicine characteristic services open up the "last mile", the list of the first batch of "Shanghai Traditional Chinese Medicine Characteristic Demonstration Community Health Service Stations (Village Health Rooms)" was announced.
